Gilead Sciences Inc.

ticker: GILD step: 01 generated: 2026-05-12 source: quick-research

Gilead Sciences, Inc. (GILD) — Business Overview

Business Description

Gilead Sciences is the global leader in HIV antiviral therapy and a growing player in oncology + liver disease + COVID-19 treatment. The HIV franchise (Biktarvy + Descovy + Genvoya legacy + new launches Yeztugo and bictegravir + lenacapavir combo) represents ~70% of revenue and ~85% of profit. After acquiring Immunomedics ($21B, 2020, Trodelvy), Kite Pharma ($12B, 2017, Yescarta CAR-T), and CymaBay ($4.3B, 2024, MASH), Gilead has built a diversified pipeline. The 2025 FDA approval of lenacapavir (Yeztugo) for HIV PrEP — twice-yearly injection is the most transformational launch in HIV prevention in a decade and represents the company's most important product cycle for the next 5+ years. No major patent expirations until 2036.

Revenue Model

Single reportable segment (organized by franchise):

• HIV ($19.6B FY24, 70% of revenue, +8% in FY24) — Biktarvy ($14B), Descovy (PrEP), Genvoya, Yeztugo (lenacapavir for PrEP, launched mid-2025), various legacy treatments.
• Oncology ($3.3B FY24, +12%) — Trodelvy (Sacituzumab govitecan TROP-2 ADC; $1.4B FY25 in breast cancer + bladder cancer + lung cancer); Yescarta (axicabtagene ciloleucel, CAR-T for lymphoma); Tecartus (CAR-T for mantle cell lymphoma).
• Liver Disease (~$3B) — Vemlidy (Hep B), Hepcludex (Hep D), legacy Hep C franchises (Epclusa, Harvoni), Livdelzi (PBC; from CymaBay).
• Veklury / COVID-19 — $911M FY25 (-49% YoY); declining as pandemic-era demand normalizes.
• Other — Cosela, Trodelvy in non-oncology, partnership revenue.

Revenue is highly recurring (mostly chronic disease treatment requiring ongoing therapy); royalty payment streams from licensing deals add stable income.

Products & Services

• Biktarvy — Once-daily oral HIV treatment; standard-of-care; ~$14B annualized. Grew +13% in FY24.
• Yeztugo (lenacapavir for PrEP) — Twice-yearly injection for HIV prevention; launched Summer 2025; 2026 sales guide raised to $1B (blockbuster status in Year 1). 72% sequential growth in Q1 2026 launch.
• Descovy — Daily oral HIV PrEP (older standard).
• Bictegravir + Lenacapavir — Investigational once-daily oral HIV treatment combo; FDA priority review, decision expected August 2026.
• Trodelvy (sacituzumab govitecan) — TROP-2 antibody-drug conjugate; metastatic breast cancer (TNBC + HR+/HER2-); bladder cancer; expanding to lung cancer.
• Yescarta + Tecartus — CAR-T cell therapies for lymphoma/leukemia from Kite.
• Veklury (remdesivir) — IV COVID-19 antiviral.
• Livdelzi — Primary biliary cholangitis (from CymaBay acquisition).
• Pipeline: Magrolimab (CD47 — discontinued in 2024); ~7 potential HIV launches by 2033 including bictegravir-lenacapavir combo, GS-1720/GS-4182 PCSK9 (HIV), domvanalimab (lung cancer), GS-3008.

Customer Base & Go-to-Market

• HIV providers: 30,000+ infectious-disease physicians, specialty pharmacies, hospitals.
• PrEP at-risk populations: gay/bisexual men, female sex workers, intravenous drug users, others. PEPFAR + Global Fund + ViiV partnerships expand access globally.
• Oncology: Academic medical centers + community oncology + cancer centers (Yescarta CAR-T at CAR-T-certified facilities).
• Hepatology: Hepatologists, gastroenterologists.
• Public Health Programs: PEPFAR ($1B+ Yeztugo procurement), Global Fund, GAVI partnerships.

Geographic mix: ~75% US, ~20% Europe, ~5% rest of world. Significant international expansion via Yeztugo low-income markets pricing.

Competitive Position

Gilead is the dominant global HIV therapeutic company. Structural advantages:

1. HIV franchise depth + Biktarvy moat — Biktarvy is the global standard for HIV treatment; 13% growth in FY24 + 7% growth in FY25 despite an ~$14B base.
2. Yeztugo (lenacapavir PrEP) first-mover advantage — Twice-yearly injection vs. daily oral pills is a step-change in PrEP convenience. Years ahead of competitors (ViiV/GSK's cabotegravir is monthly oral / every-2-months injection).
3. No major LOEs until 2036 — Multi-year patent runway is the best in big pharma; combined with strong pipeline of 7+ HIV launches by 2033, supports durable franchise.
4. Trodelvy in oncology — Best-in-class TROP-2 ADC; multi-indication expansion through 2027–28.
5. Vertical integration in HIV — Develops the molecules, conducts trials, manufactures, distributes, partners with PEPFAR/Global Fund — full-stack HIV ecosystem.

Competitive challenges:

• GSK / ViiV (cabotegravir + dolutegravir): Direct HIV competition; cabotegravir/rilpivirine long-acting injectable is ahead of US PrEP market share but losing ground to Yeztugo.
• Merck (islatravir, doravirine): Long-acting HIV pipeline.
• AbbVie + Pfizer (ADC + oncology): Direct competition in TROP-2 ADC space.
• PEPFAR + Global Fund pricing pressure: Lenacapavir supplied at no profit in low-income markets supports a path to generics; Biktarvy + premium-market pricing under fire from drug-pricing politics.
• IRA Medicare negotiation: Multiple HIV drugs eligible 2027–28.

Key Facts

• Founded: 1987
• Headquarters: Foster City, California
• Employees: ~18,000
• Exchange: NASDAQ
• Sector / Industry: Health Care / Biotechnology
• Market Cap: ~$120B
• FY2024 Revenue: $28.6B (+6% YoY)
• HIV Revenue: $19.6B (FY24); growing +8–10% in FY25
• Trodelvy Revenue: $1.4B (FY25, +6%)
• Yeztugo 2026 Revenue Guide: $1B (blockbuster Year 1)
• Veklury (COVID): $911M (FY25, declining)
• Dividend Yield: ~3.0% (Dividend Aristocrat candidate building)
• Major Recent Acquisitions: CymaBay ($4.3B, 2024); Immunomedics ($21B, 2020); Kite ($12B, 2017)

ticker: GILD step: 04 generated: 2026-05-12 source: quick-research

Gilead Sciences, Inc. (GILD) — Financial Snapshot

Income Statement Summary

Cash Flow & Capital Allocation (FY2025)

FY2026 Guidance

Key Ratios (approximate)

• P/E: ~10x (FY26 non-GAAP) | EV/EBITDA: ~7x | FCF Yield: ~7%
• Revenue Growth (FY25): +2.7% (ex-Veklury: ~+6%)
• Non-GAAP Operating Margin: ~47%
• Dividend Yield: ~3.0% | Payout Ratio: ~37% of FCF
• Net Debt / EBITDA: ~1.7x

Growth Profile

FY25 was the launch year for lenacapavir (Yeztugo) — the most transformational HIV launch since Biktarvy in 2018. Yeztugo's first full year (2026) is now guided at $1B+ in revenue — blockbuster status in Year 1. Combined with:

• Biktarvy still growing +7% YoY (at a $14B+ base)
• US PrEP business +87% in Q1 2026
• Trodelvy in expanded oncology indications
• No major patent expirations until 2036
• ~7 potential new HIV launches by 2033

Gilead's growth trajectory is the most durable in big pharma. Q1 2026 Yeztugo +72% sequential growth confirmed launch momentum is accelerating.

The Veklury decline (-49% in FY25) is the only meaningful headwind; even with Veklury fully eliminated, HIV growth more than offsets. PEPFAR + Global Fund Yeztugo procurement programs add geographic + access expansion that drives multi-decade global TAM.

Forward Estimates

FY2026 Guide:

• Revenue: $29.6–30.0B (ex-Veklury growth ~+5–6%)
• Non-GAAP EPS: $8.45–8.85 (+4–9%)
• Yeztugo: $1B+
• HIV (T+P): +8% YoY

Bull case: Yeztugo exceeds $1.5B in 2026 + reaches $5B+ peak; bictegravir-lenacapavir combo approval drives 2027 next-leg HIV growth; Trodelvy expansion into lung cancer + earlier-line breast adds $2B+ revenue; non-GAAP EPS reaches $10+ by FY27. Bear case: PrEP pricing pressure from public-health partnerships + Medicare IRA caps limit US lenacapavir profitability; Veklury decline continues; oncology pipeline disappoints. Consensus targets $115–135 vs. trading ~$95–105 (~15–35% implied upside given low valuation).

ticker: GILD step: 12 generated: 2026-05-12 source: quick-research

Gilead Sciences, Inc. (GILD) — Investment Catalysts & Risks

Bull Case Drivers

1. Yeztugo (lenacapavir for HIV PrEP) — blockbuster Year 1 trajectory — 2026 guide raised to $1B+ in first full year. Q1 2026 +72% sequential growth confirms launch. Twice-yearly injection is a step-change vs. daily oral PrEP and monthly cabotegravir. Multi-billion-peak potential ($5B+ at maturity).
2. Biktarvy + HIV franchise growth at +8–10% — Biktarvy still growing +7% on a ~$14B base; US PrEP business +87% in Q1 2026; HIV total sales (treatment + prevention) guided +8% in FY26. Largest single HIV franchise globally.
3. No major LOEs until 2036 + 7 HIV launches by 2033 — Most defensive patent runway in big pharma. Pipeline includes bictegravir-lenacapavir combo (FDA decision August 2026), various once-yearly + every-six-month formulations.
4. Trodelvy oncology expansion — TROP-2 ADC growing +6% to $1.4B FY25; multi-indication expansion (breast TNBC + HR+/HER2- + bladder + lung) creates $2–3B peak potential by 2028.
5. Compelling valuation (~10x FY26 P/E + 7% FCF yield + 3% dividend) — Significantly cheaper than big pharma peers; ~10x P/E reflects market skepticism about Yeztugo + post-Covid normalization.
6. Capital return discipline — $5.9B returned in FY25 (>50% FCF commitment) — Multi-year dividend growth + buyback yields ~7% combined.
7. PEPFAR + Global Fund Yeztugo partnerships — Public-health procurement expands global TAM; access programs accelerate Yeztugo adoption faster than typical PrEP launches.

Bear Case Risks

1. Yeztugo at no-profit pricing in low-income markets — generic path — Lenacapavir supplied to PEPFAR + Global Fund at no profit; supports path to generics. While US/Europe pricing remains premium, the public-health pricing creates structural pricing-ceiling pressure.
2. HIV drug pricing politically vulnerable — US drug-pricing politics directly targeting HIV therapies; IRA Medicare negotiation will hit multiple Gilead HIV drugs starting 2027–28. Pricing power could erode.
3. Veklury declining + headline risk — FY25 -49%; FY26 guide $600M; eventually $0. The continuing decline weighs on headline revenue growth.
4. Trodelvy competitive pressure — Other TROP-2 ADCs (Daiichi Sankyo + AstraZeneca's Datroway/datopotamab + dato-DXd) compete directly; Trodelvy's lead is shrinking.
5. Pipeline failures — Magrolimab (CD47, discontinued 2024) was a major loss. GILD's hit rate on biotech bets has been lumpy; pipeline single-asset risk persists.
6. CymaBay (Livdelzi PBC) integration — $4.3B acquisition (2024) for PBC indication; early commercial uptake matters for ROIC.
7. Aging Kite CAR-T franchise — Yescarta + Tecartus growth has plateaued; CAR-T market competition increasing (JNJ Carvykti, BMS Breyanzi, Caribou, Allogene).
8. Operating margin compression risk — Non-GAAP operating margin compressed in FY25 on M&A; if integration synergies disappoint, FY27 margins miss.

Upcoming Events

• Q2 2026 earnings (early August 2026): Yeztugo trajectory + bictegravir-lenacapavir FDA decision.
• FDA decision on bictegravir + lenacapavir oral combo: August 2026 (priority review).
• Trodelvy lung cancer Phase 3 readouts: TROPiCS-04 (urothelial), TROPiCS-02 (HR+ breast); multiple Trodelvy expansion catalysts through 2026–27.
• Lenacapavir long-acting expansion: Once-yearly + every-6-month formulations in development.
• IRA Medicare negotiation: Biktarvy, Descovy eligible for negotiation 2027–28.
• PEPFAR Yeztugo procurement disclosures: Multi-year contract expansion announcements.

Analyst Sentiment

Consensus rating is Buy / Overweight (~60% Buy, 35% Hold, 5% Sell). Price targets cluster $110–125 vs. trading ~$95–105 (~10–20% implied upside). Bull case targets ~$145 on Yeztugo scaling + Trodelvy expansion; bear case ~$80 on pricing pressure + Trodelvy competition. Morgan Stanley, Bernstein, JPM, BMO maintain Buy/Overweight; UBS at Neutral; Goldman at Buy with price target $128.

Research Date

Generated: 2026-05-12